SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank67
3Y CAGR-2.6%
5Y CAGR+5.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-2.6%/yr
Annual compound
5Y CAGR
+5.7%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $45.82M | +16.2% |
| 2024 | $39.44M | +7.9% |
| 2023 | $36.57M | -26.2% |
| 2022 | $49.53M | -31.8% |
| 2021 | $72.62M | +109.4% |
| 2020 | $34.68M | +186.3% |
| 2019 | $12.12M | - |